Technology
Celltrion’s anticancer biosimilar Vegzelma authorized for sales in Japan
Sept. 27, 2022
Celltrion’s Vegzelma, a bevacizumab anticancer biosimilar referencing Avastin, has been approved for sales in Japan, the South Korean biopharmaceutical company said Tuesday. According to Celltrion, the Japanese Ministry of Health, Labor and Welfare on Monday granted Vegzelma marketing approval for the treatment of multiple types of cancer including colorectal cancer, non-small cell lung cancer, ovarian cancer and cervical cancer. The latest sales authorization of Vegzelma came after the co